BioWorld Asia

Nov. 2, 2005

View Archived Issues

Map Of Changes Promises To Unmask Multitude Of Genes

NicOx Licenses Respiratory Drug To Topigen For 54.9M

CAT Paying $14M In Shares For Genencor Cancer Drugs

Ark's Gene Therapy Product Cerepro Under Review In EU

AM-Pharma Gets 9M In First Closing Of Series B Round

Other News To Note

CAT, Abbott Settle Humira Dispute: Abbott Pays $255M

Ending a 2-year-old dispute, Cambridge Antibody Technology plc and Abbott Laboratories reached an agreement concerning Humira royalties payable to CAT under a 1995 deal. (BioWorld International) Read More

2005's Second German IPO Prices At Low End Of Range

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...